BiomX Q3 net income $9.6M on warrant revaluation; DFO Phase 2 enrollment complete, CF topline pushed to H1 2026

BiomX Inc.

2024-Q3 EPS reported $2.45

Cash $24.7M as of Sep 30, 2024; company expects runway into Q4 2025.
R&D expenses $7.3M (+30% YoY); G&A $3.2M (+45% YoY); $801K goodwill impairment.
Net income $9.6M vs net loss $7.9M in Q3 2023 due to warrant fair value change.
BX211 DFO Phase 2 patient enrollment done; topline results expected Q1 2025.
BX004 CF Phase 2b topline delayed to H1 2026; manufacturing delays resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.